Loading…
Quality Systems Certification Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
44pct
2d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Quality Systems Certification Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a third-party quality system assessment program to accredit persons to assess whether a medical device manufacturer's quality system can ensure the safety and effectiveness or substantial equivalence of an approved medical device after certain changes, including changes in manufacturing or changes to enhance device safety. Device manufacturers with quality systems that have been certified by an accredited person are allowed to make changes to a device without submitting to the FDA the premarket notification, 30-day notice, or premarket approval supplement that would otherwise be required. An accredited person who assesses a device manufacturer's quality system must submit a summary of their assessment and, as appropriate, a certification of the quality system to the FDA within 30 days of the assessment. An assessment summary and certification is deemed accepted by the FDA 30 days after submission unless the FDA determines that additional information is needed to support certification, the assessment or certification is unwarranted, or an action other than acceptance of the certification is otherwise justified. Device manufacturers who make changes to devices without submitting a premarket notification must describe the changes in an annual summary submitted to the FDA. Changes made without submitting a 30-day notice or a premarket approval supplement must be described in a periodic report. Certifications accepted by the FDA remain in effect for two years. The FDA must report on this quality system assessment program no later than January 31, 2022. The program is terminated at the end of FY2022.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2017 · third_quarter · Health Issues
Issues related to implementation of PL 112-144, the Food and Drug Administration Safety and Innovation Act Issues related to the regulation and publication of clinical trials for medical devices Issues related to FDA public communications regarding emerging signals Issues related to implementation of the 21st Century Cures Act Issues related to the Medical Device User Fee Agreement Issues related to the competitiveness of the medical technology industry and the impact of Federal policies H.R. 2430 and S. "934" The FDA Reauthorization Act H.R. 2474 Medical Product Review Harmonization Act H.R. 2144 and SS. 1070 related to the classification of medical device accessories H.R. 2483 and S. 1183 related to modifications to medical devices S. 1069 related to postmarket regulation of medical devices H.RR. 2164 related to medical device preemption protection H.R. 2163 related to medical device reporting H.R. 2118 related to third party servicing of medical devices H.R. 1703 related to medical product communications H.R. 2026 related to medical product communications S.404 and H.R. 1736 bills to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments for granting export certifications Issues related to diagnostics regulation Issues related to diagnostics payment reform Issues related to promoting innovation in the med tech industry and improving FDA regulating procedures for devices Issues related to cybersecurity for medical technology Issues related to procurement and acquisition policies of the VA health system for medical technology and supplies Issues related to the regulation of, reimbursement for, and access to cancer diagnostics, imaging, and radiation therapies Issues related to federal regulation of the distribution and supply chain for medical devices
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
Issues related to implementation of PL 112-144, the Food and Drug Administration Safety and Innovation Act Issues related to the regulation and publication of clinical trials for medical devices Issues related to FDA public communications regarding emerging signals Issues related to implementation of the "21st Century Cures Act" Issues related to the Medical Device User Fee Agreement Issues related to the competitiveness of the medical technology industry and the impact of Federal policies H.R. 2430 and S. 934 The FDA Reauthorization Act H.R. 2474 Medical Product Review Harmonization Act H.R. 2144 and SS. 1070 related to the classification of medical device accessories H.R. 2483 and S. 1183 related to modifications to medical devices S. 1069 related to postmarket regulation of medical devices H.RR. 2164 related to medical device preemption protection H.R. 2163 related to medical device reporting H.R. 2118 related to third party servicing of medical devices H.R. 1703 related to medical product communications H.R. 2026 related to medical product communications S.404 and H.R. 1736 bills to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments for granting export certifications Issues related to diagnostics regulation Issues related to diagnostics payment reform Issues related to promoting innovation in the med tech industry and improving FDA regulating procedures for devices Issues related to cybersecurity for medical technology Issues related to procurement and acquisition policies of the VA health system for medical technology and supplies Issues related to the regulation of and access to cancer diagnostics, imaging, and radiation therapies Issues related to AHCA/BCRA
Client expense: $760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE